Literature DB >> 26482736

Minocycline exacerbates apoptotic neurodegeneration induced by the NMDA receptor antagonist MK-801 in the early postnatal mouse brain.

Ioana Inta1, Miriam A Vogt2, Anne S Vogel2, Markus Bettendorf1, Peter Gass2, Dragos Inta3.   

Abstract

NMDA receptor (NMDAR) antagonists induce in perinatal rodent cortical apoptosis and protracted schizophrenia-like alterations ameliorated by antipsychotic treatment. The broad-spectrum antibiotic minocycline elicits antipsychotic and neuroprotective effects. Here we tested, if minocycline protects also against apoptosis triggered by the NMDAR antagonist MK-801 at postnatal day 7. Surprisingly, minocycline induced widespread cortical apoptosis and exacerbated MK-801-triggered cell death. In some areas such as the subiculum, the pro-apoptotic effect of minocycline was even more pronounced than that elicited by MK-801. These data reveal among antipsychotics unique pro-apoptotic properties of minocycline, raising concerns regarding consequences for brain development and the use in children.

Entities:  

Keywords:  Caspase-3; MK-801; Minocycline; Neurodevelopment; Neurotoxicity; Schizophrenia

Mesh:

Substances:

Year:  2015        PMID: 26482736     DOI: 10.1007/s00406-015-0649-2

Source DB:  PubMed          Journal:  Eur Arch Psychiatry Clin Neurosci        ISSN: 0940-1334            Impact factor:   5.270


  27 in total

1.  Minocycline attenuates hyperlocomotion and prepulse inhibition deficits in mice after administration of the NMDA receptor antagonist dizocilpine.

Authors:  Lin Zhang; Yukihiko Shirayama; Masaomi Iyo; Kenji Hashimoto
Journal:  Neuropsychopharmacology       Date:  2007-01-17       Impact factor: 7.853

2.  Minocycline, schizophrenia and GluR1 glutamate receptors.

Authors:  Radmila Manev; Hari Manev
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2008-11-17       Impact factor: 5.067

3.  Blockade of NMDA receptors and apoptotic neurodegeneration in the developing brain.

Authors:  C Ikonomidou; F Bosch; M Miksa; P Bittigau; J Vöckler; K Dikranian; T I Tenkova; V Stefovska; L Turski; J W Olney
Journal:  Science       Date:  1999-01-01       Impact factor: 47.728

4.  The mGlu5 receptor antagonist MPEP activates specific stress-related brain regions and lacks neurotoxic effects of the NMDA receptor antagonist MK-801: significance for the use as anxiolytic/antidepressant drug.

Authors:  Dragos Inta; Dragana Filipovic; Juan M Lima-Ojeda; Christof Dormann; Natascha Pfeiffer; Fabrizio Gasparini; Peter Gass
Journal:  Neuropharmacology       Date:  2012-01-12       Impact factor: 5.250

5.  Expression of activating transcription factor-2, serum response factor and cAMP/Ca response element binding protein in the adult rat brain following generalized seizures, nerve fibre lesion and ultraviolet irradiation.

Authors:  T Herdegen; A Blume; T Buschmann; E Georgakopoulos; C Winter; W Schmid; T F Hsieh; M Zimmermann; P Gass
Journal:  Neuroscience       Date:  1997-11       Impact factor: 3.590

6.  Sensitivity of the developing rat brain to hypobaric/ischemic damage parallels sensitivity to N-methyl-aspartate neurotoxicity.

Authors:  C Ikonomidou; J L Mosinger; K S Salles; J Labruyere; J W Olney
Journal:  J Neurosci       Date:  1989-08       Impact factor: 6.167

7.  Minocycline inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease.

Authors:  M Chen; V O Ona; M Li; R J Ferrante; K B Fink; S Zhu; J Bian; L Guo; L A Farrell; S M Hersch; W Hobbs; J P Vonsattel; J H Cha; R M Friedlander
Journal:  Nat Med       Date:  2000-07       Impact factor: 53.440

8.  Deleterious effects of minocycline after in vivo target deprivation of thalamocortical neurons in the immature, metallothionein-deficient mouse brain.

Authors:  Emily G Potter; Ying Cheng; JoAnne E Natale
Journal:  J Neurosci Res       Date:  2009-05-01       Impact factor: 4.164

9.  Pharmacological blockade of GluN2B-containing NMDA receptors induces antidepressant-like effects lacking psychotomimetic action and neurotoxicity in the perinatal and adult rodent brain.

Authors:  Juan M Lima-Ojeda; Miriam A Vogt; Natascha Pfeiffer; Christof Dormann; Georg Köhr; Rolf Sprengel; Peter Gass; Dragos Inta
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2013-04-30       Impact factor: 5.067

Review 10.  Profile of minocycline and its potential in the treatment of schizophrenia.

Authors:  Lulu Zhang; Jingping Zhao
Journal:  Neuropsychiatr Dis Treat       Date:  2014-06-17       Impact factor: 2.570

View more
  5 in total

Review 1.  Microglia Activation and Schizophrenia: Lessons From the Effects of Minocycline on Postnatal Neurogenesis, Neuronal Survival and Synaptic Pruning.

Authors:  Dragos Inta; Undine E Lang; Stefan Borgwardt; Andreas Meyer-Lindenberg; Peter Gass
Journal:  Schizophr Bull       Date:  2017-05-01       Impact factor: 9.306

2.  Effects of α7 Nicotinic Receptor Activation on Cell Survival in Rat Organotypic Hippocampal Slice Cultures.

Authors:  Denise F Happ; R Andrew Tasker
Journal:  Neurotox Res       Date:  2017-12-22       Impact factor: 3.911

3.  Pediatric use of tetracyclines: focus on neurodevelopmental effects.

Authors:  Ioana Inta; Georg F Hoffmann; Markus Bettendorf
Journal:  Pediatr Res       Date:  2017-08-02       Impact factor: 3.756

4.  Rapastinel alleviates the neurotoxic effect induced by NMDA receptor blockade in the early postnatal mouse brain.

Authors:  Peter Gass; Dragos Inta; Andrei-Nicolae Vasilescu; Anne Mallien; Natascha Pfeiffer; Undine E Lang
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2020-08-13       Impact factor: 5.270

5.  Minocycline for the treatment of mental health and neurological conditions: study protocol of a systematic review and meta-analysis.

Authors:  Chiara C Bortolasci; Wolfgang Marx; Adam J Walker; Kyoko Hasebe; Bianca E Kavanagh; Margaret J Morris; Mohammadreza Mohebbi; Alyna Turner; Laura Gray; Lesley Berk; Ken Walder; Michael Berk; Olivia M Dean
Journal:  BMJ Open       Date:  2020-03-19       Impact factor: 2.692

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.